Susruta Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 09-12-2024
- Paid Up Capital ₹ 0.50 M
as on 09-12-2024
- Company Age 11 Year, 1 Month
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 7.00 M
as on 09-12-2024
- Revenue -25.85%
(FY 2022)
- Profit 21.63%
(FY 2022)
- Ebitda 58.35%
(FY 2022)
- Net Worth -39.25%
(FY 2022)
- Total Assets -21.95%
(FY 2022)
About Susruta Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹7.00 M.
Subhashree Das, Bhaskar Das, and Subir Chatterjee serve as directors at the Company.
- CIN/LLPIN
U74900WB2013PTC198456
- Company No.
198456
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Nov 2013
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Susruta Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subhashree Das  | Director | 19-Nov-2013 | Current |
| Bhaskar Das | Director | 20-Mar-2014 | Current |
| Subir Chatterjee | Director | 10-Mar-2023 | Current |
Financial Performance and Corporate Structure Insights of Susruta Pharmaceuticals.
Susruta Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 25.85% decrease. The company also saw a substantial improvement in profitability, with a 21.63% increase in profit. The company's net worth observed a substantial decline by a decrease of 39.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Susruta Pharmaceuticals?
Unlock access to Susruta Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 May 2016 | ₹4.50 M | Open |
Oriental Bank Of Commerce Creation Date: 02 Apr 2015 | ₹2.50 M | Open |
How Many Employees Work at Susruta Pharmaceuticals?
Unlock and access historical data on people associated with Susruta Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Susruta Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Susruta Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
